First-Line Therapies for VTE Treatment and Secondary Prophylaxis in Patients With Cancer: A New Direction

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Cancer patients face a higher risk of venous thromboembolism (VTE).
• Traditional anticoagulants like low-molecular-weight heparins (LMWH) and vitamin K antagonists (VKAs) have limitations in managing VTE in this population.
• Direct oral anticoagulants (DOACs) are emerging as potential alternatives.

Purpose of the Study:

• To review the evidence for anticoagulants in cancer-associated VTE.
• To specifically evaluate low-molecular-weight heparins (LMWH) and direct oral anticoagulants (DOACs).
• To assess the efficacy and safety of DOACs compared to traditional therapies.

Main Methods:

• Systematic literature search of PubMed for clinical trials, meta-analyses, and subgroup analyses.
• Inclusion of prospective and retrospective studies on LMWH and DOACs in cancer patients.
• Analysis of comparative trials assessing recurrent VTE prevention and treatment.

Main Results:

• Studies comparing LMWH and VKAs showed nonsignificant differences in efficacy, with one study suggesting LMWH superiority, though limited by methodological concerns.
• Subanalyses of DOAC trials indicate comparable or superior efficacy to VKAs in cancer patients, but these findings are underpowered.
• DOACs present an opportunity to overcome challenges associated with conventional anticoagulant therapies.

Conclusions:

• DOACs demonstrate potential to simplify VTE management in cancer patients.
• Despite limitations in current evidence, DOACs are a reasonable treatment option for VTE in cancer patients.
• Careful consideration of individual patient risks and benefits is crucial when selecting anticoagulation therapy.